Form 4: IRADIMED CORP: Insider Sells Shares Under 10b5-1 Plan

Roger E. Susi, CEO and Director of IRADIMED CORP, reported the sale of common stock totaling 2,669 shares, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Roger E. Susi, who holds the positions of CEO, President, Chairman, Director, and is a 10% owner of IRADIMED CORP, has reported transactions involving the sale of company stock.
• These sales occurred on June 1, 2026, and were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025.
• The total number of shares sold across multiple transactions was 2,669.
• The sales were executed at weighted average prices ranging from $88.68 to $91.91 per share.
• Following these transactions, Susi's beneficial ownership of IRADIMED CORP common stock is detailed, with holdings attributed to various trusts and his revocable trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider selling, the transactions were conducted under a pre-established Rule 10b5-1 plan, which is a standard compliance mechanism and does not inherently signal negative sentiment about the company's prospects.

Negatives

• Insider selling activity, particularly by a CEO and significant shareholder, can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established trading plan.

Risks

• The Rule 10b5-1 plan is designed to provide an affirmative defense against allegations of insider trading, but the execution of such plans can still be subject to market interpretation.
• While not explicitly stated as a risk in this filing, significant insider selling could potentially signal a lack of confidence in near-term stock performance, though the plan's existence mitigates this interpretation.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a CEO of a medical technology company like IRADIMED CORP is a common practice to manage personal stock sales in a way that avoids potential insider trading concerns, especially during periods of blackout restrictions or before significant company news.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive might be monitored, but the Rule 10b5-1 plan mitigates concerns about adverse insider trading implications.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Continued adherence to the Rule 10b5-1 trading plan for any future scheduled sales.
• Potential for further disclosures on Form 4 if additional transactions occur.

Key Dates

Keywords

IRADIMED CORP, IRMD, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, CEO, Director, Securities Exchange Act